Physician

Scott A Hebert, M.D.

According to 2025 Medicare claims, Scott Hebert, M.D. (NPI: 1548603996) practices hematology/oncology in the Houma-Bayou Cane-Thibodaux, LA market, with the plurality of this provider's patient population coming from Lafourche, LA. This provider's primary affiliated billing organization is THIBODAUX REGIONAL NETWORK DEVELOPMENT CORPORATION (NPI: 1295069490; TIN: 721335958) and primary practice location at 70301-4847. Hebert is affiliated with the Ochsner Accountable Care Network, LLC (ACO ID: A1535), participating under the MSSP model.

Hebert's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 407 traditional Medicare patients, billed 4,615 HCPCS/CPT codes, and received $264,134 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 3,557 prescription claims across 393 beneficiaries totaling $5,854,452 in drug costs, led by Revlimid (Lenalidomide). DME data shows 15 claims. Open Payments data shows 19 records totaling $451. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $2,372 to $264,134. Similarly, Part D prescription costs have moved sharply higher in recent years, from $32,094 to $5,854,452. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	19	30	$2,372
2016	82	151	$9,662
2017	82	153	$10,348
2018	172	265	$15,752
2019	314	626	$41,570
2020	301	1,682	$134,142
2021	284	2,231	$212,676
2022	304	2,310	$223,522
2023	374	2,456	$216,255
2024	407	4,615	$264,134

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	79	468	$32,094
2016	112	513	$72,900
2017	99	321	$226,615
2018	98	406	$395,486
2019	107	450	$548,431
2020	171	1,349	$1,531,273
2021	219	2,000	$3,263,481
2022	274	2,686	$3,155,088
2023	307	2,839	$4,193,535
2024	393	3,557	$5,854,452

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	15	$694

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	68	68	$131
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	290	1,748	$98
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	194	382	$68
G2212	Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	121	288	$23
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	307	1,769	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	57	1,547	$1,064,825
Verzenio	Abemaciclib	37	1,036	$574,547
Jakafi	Ruxolitinib Phosphate	32	950	$561,193
Calquence	Acalabrutinib Maleate	35	1,022	$521,942
Lenalidomide	Lenalidomide	44	1,064	$509,346

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8700	Temozolomide, oral, 5 mg	N	N/R	15	$694

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	19	$451	US Oncology Corporate, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Scott A. Hebert, M.D.?

Tedicare shows public-source Medicare data for Scott A. Hebert, M.D. (NPI 1548603996), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Scott A. Hebert, M.D. have ACO affiliation data?

Scott A. Hebert, M.D. is shown with ACO affiliation data for Ochsner Accountable Care Network, LLC (MSSP, ACO ID A1535).

What billing organization is linked to Scott A. Hebert, M.D.?

Scott A. Hebert, M.D. is linked to THIBODAUX REGIONAL NETWORK DEVELOPMENT CORPORATION (billing NPI 1295069490) in the available physician profile data.

Does Scott A. Hebert, M.D. have Open Payments data?

Scott A. Hebert, M.D. has 19 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.